MDXH

MDxHealth SA (MDXH) | Rumor.io

MDxHealth SA

MDXH

Attention (50-day avg)0%

Attention rank (50-day avg)#1,212

Bullish sentiment (50-day avg)87%

Price to earnings ratio-0.82

Market capitalization52.3M

Earnings per share-0.69

Dividend yield (TTM)—

Revenue (annual)107.9M

Net income (annual)-33.5M

Social

What share of all stock conversation is about MDXH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 17

MDXHealth S.A. ($MDXH) is looking good on its 4-hour chart, with a key support zone at 0.54-0.58 and a next key level to test at 0.89-0.93.
The stock has surprised some investors with its recent performance, with one user predicting a price of $2 by the end of the week.
MDXHealth's financing risk is a concern, with one user noting that at the micro-cap tier, financing risk is a dominant driver, and the company's ability to stay afloat is uncertain.

Generated by AI

Sentiment

Of the messages about MDXH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +13.13	89.47% -7.08
Bearish	—	—	0% -13.13	10.53% +7.08

Bullish· Aug 14

The CEO has been actively buying shares, indicating confidence in the company's future.
The company has reported its highest quarterly revenue in eight quarters, returned to profitability, and achieved a significant increase in EPS.
With a strong fundamental base and a history of successful expansion into new markets, the company is poised for significant growth and a potential 600% day.

Bearish· Aug 14

The stock has been "disappointing" and is dropping like a stone, prompting some to suggest buying a different stock instead ($VBIO).
The company's stock is seen as "corrupt" and some are predicting a shakeout before a potential price increase.
The stock's inability to hold above $1 has led some investors to sell and predict a return to $0.6.

Generated by AI

Topics

Of the messages about MDXH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	—	—	0%	4.67%
Announcements	—	—	100%	42.99%
Technical Analysis	—	—	0%	34.11%
Analysts	—	—	0%	12.15%
Macro	—	—	0%	6.07%
Controversies	—	—	0%	0%

Announcements· Feb 3

MDxHealth S.A. announces a $40 million stock offering at $4 per share.
The offering is a private placement of shares, with the exact terms and details not specified.
The announcement aims to raise capital for the company's growth and development.

Technical Analysis· Aug 14

The stock experienced a significant surge in volume, with 324M shares traded, compared to an average of ~200K two weeks ago, indicating a potential strong trend.
The stock's recent price action, with a spike and subsequent pullback, suggests that it may be forming a double bottom or a bull flag, which could be a sign of a potential breakout.
The stock's technical indicators, such as the Relative Strength Index (RSI), suggest that it is still in a bullish trend, with the RSI staying hot and the chart carving a bullish setup, indicating that the bulls are in control.

Generated by AI

Community

Of the messages about MDXH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	8.88%
Newcomers	—	—	100%	91.12%

Regulars· Aug 14

The company has a 90-day mandatory holding period, which could be seen as bullish, and may lead to a market cap above $40 million.
The stock has a market cap of around $50-55 million, with the potential to regain compliance above $35 million in 10 trading days.
The stock is showing signs of a bullish setup, with a surge in volume and a hot RSI, and is nearing a new high of the day.

Newcomers· Aug 17

The MDxHealth S.A. stock price is currently around $0.71, with a key support zone at $0.54-$0.58 and a next key level to test at $0.89-$0.93.
Some newcomers are predicting a price increase to $2, with one user even going as far as to predict $5, while others are more cautious, setting sell orders for $2.
The stock has been experiencing significant price drops, with one user noting a loss of 50% from its high on Friday, and another user questioning the legitimacy of the price movements, calling it "manipulation".

Generated by AI

MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch...

25d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Revolution Medicines (RVMD) and MDxHealth (MDXH)

Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

BTIG cuts MDxHealth stock price target on higher share count

1mo agoInvesting.com

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

Detailed price information for Mdxhealth Sa ADR (MDXH-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

1mo agoBenzinga

Also Discussed

Investors talking about MDXH also mention

#	Name	Attention
1	Mangoceuticals, Inc.MGRX	0%0
2	Rocky Mountain Chocolate Factory, Inc.RMCF	0%0
3	PDS Biotechnology CorporationPDSB	0%-0.01
4	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
5	FIAC - Focus Impact Acquisition Corp.	——
6	First Trust SMID Cap Rising Dividend Achievers ETFSDVY	0%new
7	Vox Royalty Corp. Common StockVOXR	0%new
8	Commercial Vehicle Group IncCVGI	0%0
9	KACL - Kairous Acquisition Corp. Limited	——
10	Apollomics Inc.APLM	0%0

MDxHealth SA

Healthcare
Diagnostics & Research

MDxHealth SA is a commercial-stage precision diagnostics company focused on molecular testing for urologic diseases. MDxHealth SA develops and commercializes diagnostic solutions that help physicians assess the presence, risk, and management of prostate cancer, bladder cancer, and urinary tract infections. Its portfolio includes tissue- and urine-based tests that use genomic, epigenetic, exosomal, and other molecular technologies to support more informed clinical decision-making. The company serves healthcare providers and patients across the United States, Europe, and other international markets, with laboratory and commercial operations supporting the delivery of its tests. MDxHealth SA plays a role in the broader diagnostics market by providing actionable molecular information designed to improve the precision of cancer and infection diagnosis and treatment planning.

Website

Location

CAP Business Center

Herstal, 4040

Belgium

Social

What share of all stock conversation is about MDXH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Aug 17

MDXHealth S.A. ($MDXH) is looking good on its 4-hour chart, with a key support zone at 0.54-0.58 and a next key level to test at 0.89-0.93.
The stock has surprised some investors with its recent performance, with one user predicting a price of $2 by the end of the week.
MDXHealth's financing risk is a concern, with one user noting that at the micro-cap tier, financing risk is a dominant driver, and the company's ability to stay afloat is uncertain.

Generated by AI

Sentiment

Of the messages about MDXH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +13.13	89.47% -7.08
Bearish	—	—	0% -13.13	10.53% +7.08

Bullish· Aug 14

The CEO has been actively buying shares, indicating confidence in the company's future.
The company has reported its highest quarterly revenue in eight quarters, returned to profitability, and achieved a significant increase in EPS.
With a strong fundamental base and a history of successful expansion into new markets, the company is poised for significant growth and a potential 600% day.

Bearish· Aug 14

The stock has been "disappointing" and is dropping like a stone, prompting some to suggest buying a different stock instead ($VBIO).
The company's stock is seen as "corrupt" and some are predicting a shakeout before a potential price increase.
The stock's inability to hold above $1 has led some investors to sell and predict a return to $0.6.

Generated by AI

Topics

Of the messages about MDXH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	—	—	0%	4.67%
Announcements	—	—	100%	42.99%
Technical Analysis	—	—	0%	34.11%
Analysts	—	—	0%	12.15%
Macro	—	—	0%	6.07%
Controversies	—	—	0%	0%

Announcements· Feb 3

MDxHealth S.A. announces a $40 million stock offering at $4 per share.
The offering is a private placement of shares, with the exact terms and details not specified.
The announcement aims to raise capital for the company's growth and development.

Technical Analysis· Aug 14

The stock experienced a significant surge in volume, with 324M shares traded, compared to an average of ~200K two weeks ago, indicating a potential strong trend.
The stock's recent price action, with a spike and subsequent pullback, suggests that it may be forming a double bottom or a bull flag, which could be a sign of a potential breakout.
The stock's technical indicators, such as the Relative Strength Index (RSI), suggest that it is still in a bullish trend, with the RSI staying hot and the chart carving a bullish setup, indicating that the bulls are in control.

Generated by AI

Community

Of the messages about MDXH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	8.88%
Newcomers	—	—	100%	91.12%

Regulars· Aug 14

The company has a 90-day mandatory holding period, which could be seen as bullish, and may lead to a market cap above $40 million.
The stock has a market cap of around $50-55 million, with the potential to regain compliance above $35 million in 10 trading days.
The stock is showing signs of a bullish setup, with a surge in volume and a hot RSI, and is nearing a new high of the day.

Newcomers· Aug 17

The MDxHealth S.A. stock price is currently around $0.71, with a key support zone at $0.54-$0.58 and a next key level to test at $0.89-$0.93.
Some newcomers are predicting a price increase to $2, with one user even going as far as to predict $5, while others are more cautious, setting sell orders for $2.
The stock has been experiencing significant price drops, with one user noting a loss of 50% from its high on Friday, and another user questioning the legitimacy of the price movements, calling it "manipulation".

Generated by AI

MDxHealth SA

Social

Aug 17

Bullish· Aug 14

Bearish· Aug 14

Announcements· Feb 3

Technical Analysis· Aug 14

Regulars· Aug 14

Newcomers· Aug 17

MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Revolution Medicines (RVMD) and MDxHealth (MDXH)

BTIG cuts MDxHealth stock price target on higher share count

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

Also Discussed

MDxHealth SA

Company Information

Location

MDxHealth (MDXH) Stock Sees Fair Value Cut As Analysts Weigh Dilution And Execution

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), Revolution Medicines (RVMD) and MDxHealth (MDXH)

BTIG cuts MDxHealth stock price target on higher share count

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

Also Discussed

Social

Aug 17

Bullish· Aug 14

Bearish· Aug 14

Announcements· Feb 3

Technical Analysis· Aug 14

Regulars· Aug 14

Newcomers· Aug 17